Micronoma is a San Diego-based startup that operates in the healthcare sector, specifically in the field of cancer diagnostics. The company is pioneering the use of microbiome markers in blood to detect early-stage cancer, a method known as a liquid biopsy. This innovative approach has the potential to revolutionize cancer detection by identifying the disease in its earliest stages (I and II), when it is most treatable.

Micronoma's primary product is the Oncobiota™ platform, which combines microbial research, next-generation sequencing, and artificial intelligence to achieve high levels of sensitivity and specificity in cancer detection. The company is initially focusing on lung cancer, but plans to expand its services to other types of cancer in the future.

The company's business model involves partnering with physicians and healthcare providers to integrate its advanced diagnostic services into their practices. By providing physicians with targeted tools for early cancer detection, Micronoma aims to deliver actionable results that can lead to cost savings and, more importantly, save lives.

Micronoma generates revenue by selling its diagnostic services to healthcare providers. The company's recent collaboration with the NYU Grossman School of Medicine and the receipt of an FDA Breakthrough Device designation for its OncobiotaLUNG assay are significant milestones that could potentially boost its market position and revenue growth.

Keywords: Micronoma, cancer diagnostics, liquid biopsy, microbiome markers, early-stage cancer detection, Oncobiota™ platform, lung cancer, healthcare providers, FDA Breakthrough Device, NYU Grossman School of Medicine collaboration.